Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches

Ferdous, Shifat-E; Ferrell, Jessica M.

doi:10.3390/ijms25168731

Open AccessReview

Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches

by

Shifat-E Ferdous

^1,2 and

Jessica M. Ferrell

^1,2,*

¹

Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA

²

School of Biomedical Sciences, Kent State University, Kent, OH 44242, USA

^*

Author to whom correspondence should be addressed.

Int. J. Mol. Sci. 2024, 25(16), 8731; https://doi.org/10.3390/ijms25168731

Submission received: 28 June 2024 / Revised: 8 August 2024 / Accepted: 9 August 2024 / Published: 10 August 2024

(This article belongs to the Special Issue New Advances in Type 2 Diabetes and Its Complications)

Download

Browse Figures

Review Reports Versions Notes

Abstract

Type 2 diabetes mellitus (T2DM), often featuring hyperglycemia or insulin resistance, is a global health concern that is increasing in prevalence in the United States and worldwide. A common complication is metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of metabolic syndrome that is also rapidly increasing in prevalence. The majority of patients with T2DM will experience MASLD, and likewise, individuals with MASLD are at an increased risk for developing T2DM. These two disorders may act synergistically, in part due to increased lipotoxicity and inflammation within the liver, among other causes. However, the pathophysiological mechanisms by which this occurs are unclear, as is how the improvement of one disorder can ameliorate the other. This review aims to discuss the pathogenic interactions between T2D and MASLD, and will highlight novel therapeutic targets and ongoing clinical trials for the treatment of these diseases.

Keywords: hyperglycemia; steatosis; liver disease; metabolic disease; MASLD

Share and Cite

MDPI and ACS Style

Ferdous, S.-E.; Ferrell, J.M. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches. Int. J. Mol. Sci. 2024, 25, 8731. https://doi.org/10.3390/ijms25168731

AMA Style

Ferdous S-E, Ferrell JM. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches. International Journal of Molecular Sciences. 2024; 25(16):8731. https://doi.org/10.3390/ijms25168731

Chicago/Turabian Style

Ferdous, Shifat-E, and Jessica M. Ferrell. 2024. "Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches" International Journal of Molecular Sciences 25, no. 16: 8731. https://doi.org/10.3390/ijms25168731

APA Style

Ferdous, S.-E., & Ferrell, J. M. (2024). Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches. International Journal of Molecular Sciences, 25(16), 8731. https://doi.org/10.3390/ijms25168731

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI